Company Encyclopedia
View More
name
DiaMedica Therapeutics
DMAC.US
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc.
1.945 T
DMAC.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Buy Rating Affirmed for Diamedica Therapeutics Amid Promising DM199 Trial Progress

    H.C. Wainwright analyst Matthew Caufield reaffirmed a Buy rating for Diamedica Therapeutics, citing promising progress in DM199 trials for preeclampsia and acute ischemic stroke. The company has completed Part 1a of the Phase 2 preeclampsia trial and initiated a pre-IND meeting with the FDA. Positive interim results and strategic FDA discussions support the Buy rating with a $12 price target. Cantor Fitzgerald also initiated coverage with a Buy rating and a $25 price target.

    Tip Ranks·
    US
    DMAC
    +0.98%
    Tip Ranks·
    US
    DMAC
    +0.98%

    Lake Street Sticks to Its Buy Rating for Diamedica Therapeutics (DMAC)

    Lake Street analyst Thomas Flaten maintains a Buy rating for Diamedica Therapeutics with a $14.00 price target. Flaten, who covers the Healthcare sector, has an average return of 18.0% and a 54.15% success rate. Diamedica has a Strong Buy consensus with a $17.00 price target.

    Tip Ranks·
    US
    DMAC
    +0.98%
    Tip Ranks·
    US
    DMAC
    +0.98%

    DiaMedica Therapeutics Reports Q3 2025 Financial Results

    DiaMedica Therapeutics reported Q3 2025 financial results, highlighting progress in clinical trials for preeclampsia and acute ischemic stroke. The company completed a milestone in its Phase 2 trial for preeclampsia and advanced its ReMEDy2 trial. DiaMedica's cash position improved to $55 million, supporting operations into 2027, despite a net loss of $8.6 million due to increased R&D expenses. The company remains optimistic about its lead candidate, DM199, and continues collaboration with regulatory bodies.

    Tip Ranks·
    US
    DMAC
    +0.98%
    Tip Ranks·
    US
    DMAC
    +0.98%

    DiaMedica Therapeutics’ Earnings Call: Mixed Outlook

    DiaMedica Therapeutics' Q3 earnings call revealed mixed results. The company showed progress in its preeclampsia program with positive interim results, but faces challenges with slow enrollment in the ReMEDy2 stroke trial and rising operating expenses. Despite these hurdles, DiaMedica maintains a strong cash position of $55.3 million. The company plans to expand its clinical programs, with completion of the preeclampsia study expected in early 2026 and interim analysis of the stroke trial in late 2026. Investors are watching closely as these developments unfold.

    Tip Ranks·
    US
    DMAC
    +0.98%
    Tip Ranks·
    US
    DMAC
    +0.98%

    DiaMedica Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    DMAC
    +0.98%
    LB filings·
    US
    DMAC
    +0.98%
    © 2025 Longbridge｜Disclaimer